Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HCV Coinfection Clear all

Conditions: Hepatitis C, Hepatitis B
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1991
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatitis C, HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2015
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Hepatitis B, Hepatitis C, HIV-HCV Co-Infection
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 569 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: HIV Infections, Hepatitis C
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 65 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C, People Who Inject Drugs, PWID, HCV Coinfection
Interventions: Accessible Care, Usual Care; Other
Lead sponsor: City University of New York, School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Liver Fibrosis, Hepatitis C, HIV, HIV/HCV Co-infection
Interventions: Simtuzumab; Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections, Hepatitis C
Interventions: Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), Dasabuvir (DSV), Ribavirin (RBV); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more

Conditions: Hepatitis, HIV/AIDS
Interventions: Boceprevir, Peg-Interferon-alfa 2B, Ribavirin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Hepatitis C Virus, Hiv Infections
Interventions: bavituximab; Drug
Lead sponsor: Peregrine Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 6
States / cities: Los Angeles, California • Newport Beach, California • Atlanta, Georgia + 3 more

Conditions: Hepatitis C
Interventions: Daclatasvir, Sofosbuvir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 37
States / cities: Birmingham, Alabama • Beverly Hills, California • Long Beach, California + 27 more

Conditions: Hepatitis C and HIV Coinfection
Interventions: Blood draws for tenofovir PK, renal function; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: HCV HIV
Interventions: Ledipasvir 90 mg and Sofosbuvir 400 mg; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Hepatitis C, HIV Infections
Interventions: Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: Cincinnati, Ohio • Richmond, Virginia

Conditions: Thrombocytopenia, Hepatitis C, HIV Infections
Interventions: Anti-D; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infection, Hepatitis C
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 1,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hepatitis C, HIV
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections, Hepatitis C, Hemophilia
Interventions: Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 15 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hepatitis C, HIV Infections
Interventions: telaprevir or matching placebo, peginterferon alfa-2a, ribavirin (fixed dose), ribavirin (weight-based dose); Drug · Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 11
States / cities: Beverly Hills, California • San Diego, California • San Francisco, California + 8 more

Conditions: Hepatitis C Virus Infection
Interventions: SOF/VEL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 12 more

Conditions: Treatment of Hepatitis C
Interventions: Ledipasvir/Sofosbuvir FDC; Drug
Lead sponsor: Peter J. Ruane, M.D., Inc.; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV Infections, Hepatitis
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 634 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: HIV, Hepatitis C, Liver Disease, Fatty Liver, Steatosis
Interventions: Pioglitazone, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: HIV, Hepatitis C, Infections
Interventions: Pegylated interferon alfa and ribavirin (PEG-IFN/RBV); Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 4
States / cities: Lancaster, California • Los Angeles, California

Conditions: Hepatitis C, Human Immunodeficiency Virus, HIV Infections
Interventions: Pegylated interferon alfa-2a + Ribavirin; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection

Leukapheresis for Research on HCV-Coinfected Patients

Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection

Effects of HIV and Hepatitis C Virus on the Brain

Accessible HCV Care Intervention for People Who Inject Illicit Drugs (PWID)

Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis

Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy

Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV

Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus

A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.

Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir

Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia

Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV

Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection

HCV/HIV Coinfection: Antiviral Therapy and Fibrosis

Open Label Study to Evaluate Chronic Hepatitis C Treatment in Latino Subjects With and Without HIV Co-infection

Treatment of Hepatitis C in Hemophilic Patients With HIV

Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection

HIV-HCV Coinfection: Impact of Immune Dysfunction

Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections

Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy

Treatment of Acute Hepatitis C Virus in HIV Co-Infection